The win­dow is wide open as four more biotechs join the go-go IPO class of 2020

It’s an­oth­er day of haul­ing cash in the bio­phar­ma world as four more IPOs priced Fri­day and a fifth filed its ini­tial pa­per­work.

The biggest of­fer­ing comes from PMV Phar­ma, an on­col­o­gy biotech fo­cus­ing on p53 mu­ta­tions, which raised $211.8 mil­lion af­ter pric­ing shares at $18 apiece. Pre­lude Ther­a­peu­tics, de­vel­op­ing PRMT5 in­hibitors for rare can­cers, was next with a $158 mil­lion raise, pric­ing shares at $19 each. Gray­bug Vi­sion raised $90 mil­lion af­ter pric­ing at $16 per share for its wet AMD can­di­dates, and breast can­cer biotech Green­wich Life­sciences brought up the rear with a small, $7 mil­lion raise af­ter pric­ing shares at $5.75.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER